One of the compounds showing a strong ability to irreversibly inhibit CPT1 (CPT1A and CPT1B), is glycidyl acid derivate etomoxir (ethyl-2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate), which had been used in the treatment of type 2 diabetes and chronic heart failure. Here, CPT1A is linked to type 2 diabetes mellitus.